Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of bilastine ophthalmic solution 0.6% in adults with allergic conjunctivitis
2018-002248-95Phase 3Completed
- Sponsor
- Faes Farma
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing Bilastine ophthalmic solution 0.6% with Placebo ophthalmic solution (2 arms). Primary endpoint: Incidence of related treatment-emergent ocular adverse events (ocular r-TEAEs). Started Aug 2018; status: completed.
02
Drugs
bilastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2018-002248-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002248-95.